Crinetics Pharmaceuticals CRNX 深 滬
已收盤 08-08 16:00:00 美东时间
26.85
-1.030
-3.69%
華盛通- 最 高28.095
- 今 開27.73
- 成交量 200.36万股
- 最 低 25.83
- 昨 收 27.88
- 總市值 25.15亿
- 52周最高 62.53
- 市盈率 靜 --
- 換手率 2.14%
- 52周最低 24.10
- 委 比 -91.17%
- 總股本 9368.01万
- 歷史最高 62.53
- 量 比 1.72
- 振 幅 8.12%
- 歷史最低 10.63
- 每 手 1
- 風險率 11.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported Q2 2025 financial results, highlighting progress toward its acromegaly drug PALSONIFY™ with an FDA PDUFA date of Sept 25, 2025. The company advanced multiple clinical programs, including atumelnant for CAH, and presented data at major medical meetings. Cash reserves of $1.2B are expected to support operations into 2029.
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data from Crinetics' clinical trials show that PALSONIFY (paltusotine), an oral treatment for acromegaly, demonstrated durable control of IGF-1 levels, reduced symptom burden, and was well-tolerated during long-term use. Results from the PATHFNDR-1 and PATHFNDR-2 open-label extensions, presented at ENDO 2025, highlight PALSONIFY's potential as a next-generation therapy for acromegaly. In PATHFNDR-1, 91% of participants transitioned to the open-...
07-13 21:45
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>Cisinetics Pharmaceuticals announced it will report its second quarter 2025 financial results on August 7, 2025 after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Participants can join via phone using domestic number 1 833-470-1428 or international number 1 404-975-4839 with access code 899803. The call will also be webcast live and archived on the company's website...
07-11 12:00
Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting
The latest announcement is out from Crinetics Pharmaceuticals ( ($CRNX) ). On J...
07-01 04:52
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
<p>San Diego, June 30, 2025. Crinetics Pharmaceuticals announced eight abstracts from its novel clinical programs, including PALSONIFY™ (paltusotine) and atumelnant, will be presented at ENDO 2025 in San Francisco. PALSONIFY continues to show long-term efficacy and safety in acromegaly patients, whether switching treatments or newly untreated. Atumelnant’s Phase 2 results in congenital adrenal hyperplasia (CAH) will be highlighted, along with upd...
06-30 20:05
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $81 price target.
06-27 19:13
Crinetics Pharmaceuticals Unveils Promising Preclinical Pipeline
Crinetics Pharmaceuticals ( ($CRNX) ) just unveiled an announcement. On June 26...
06-27 04:48
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host an in-person and virtual R&D Day on June 26, 2025, in New York. The event will provide updates on their early-stage pipeline assets, including NETs with CRN09682, Graves' disease, and ADPKD. A live Q&A session will follow. Registration is available through the provided link.
06-16 12:00
